Description
NCI-H929 is a human B lymphocyte, suspension cell line derived from the bone marrow of a patient with advanced multiple myeloma (62-year-old female). This cell line’s surface antigen profile is: PCA-1 +, CD38+, CD138+, CD19+, CD45+, CD56+, CD40+, CD54+, CD20-, CD10-, CD34-, CD14-, CD3-, HLA-DR -, EBNA-.
NCI-H929 is extensively used for studying multiple myeloma other B-cell malignancies. The cell line is used in the development and testing of immunotherapies, including monoclonal antibodies and CAR-T cell therapies, aimed at the surface antigens.
This Luciferase & GFP / human NCI-H929 (B Lymphocyte) cell line was transformed via Lentivirus transduction. It has the Luciferase and GFP was constitutively co-expressed under EF1a promoter, as two separate proteins (not as fusion), mediated via 2A element. The Puromycin resistance marker was expressed under Rsv promoter. The following express cassette was integrated into cell-line’s genome.
Each cell demonstrates a strong GFP fluorescent signal. Its chem-luminescence signal was verified via luciferase assay using the D-luciferin substrate. And its signal can be detected, in vitro and in vivo.
Sold at: 1 vial x (2 x 106 cells)/vial, see details in Product Manual.
Cat# SC099-LG
